Advanced search
Publication Cover
Sequential Analysis
Design Methods and Applications
Volume 41, 2022 - Issue 3
Submit an article Journal homepage
122
Views
0
CrossRef citations to date
0
Altmetric
Articles

Patient-specific dose finding in seamless phase I/II clinical trials

M. Iftakhar AlamInstitute of Statistical Research and Training, University of Dhaka, Dhaka, BangladeshCorrespondence[email protected]
&
Shantonu Islam ShantoInstitute of Statistical Research and Training, University of Dhaka, Dhaka, Bangladesh
Pages 367-386 | Received 11 Feb 2022, Accepted 19 Jul 2022, Published online: 13 Sep 2022

REFERENCES

  • Alam, M. I., D. S. Coad, and B. Bogacka. 2019. “Combined Criteria for Dose Optimisation in Early Phase Clinical Trials.” Statistics in Medicine 38 (21):4172–88. doi:10.1002/sim.8292
  • Bandyopadhyay, U., A. Biswas, and R. Bhattacharya. 2007. “A Covariate Adjusted Two-Stage Allocation Design for Binary Responses in Randomized Clinical Trials.” Statistics in Medicine 26 (24):4386–99. doi:10.1002/sim.2869
  • Braun, T. M. 2002. “The Bivariate Continual Reassessment Method: Extending the CRM to Phase I Trials of Two Competing Outcomes.” Controlled Clinical Trials 23 (3):240–56. doi:10.1016/S0197-2456(01)00205-7
  • Cheung, Y. K. 2014. “Simple Benchmark for Complex Dose Finding Studies.” Biometrics 70 (2):389–97. doi:10.1111/biom.12158
  • Cotterill, A., and T. Jaki. 2018. “Dose-Escalation Strategies Which Use Subgroup Information.” Pharmaceutical Statistics 17 (5):414–36. doi:10.1002/pst.1860
  • Cunningham, D., Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, et al. 2004. “Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer.” New England Journal of Medicine 351 (4):337–45. doi:10.1056/NEJMoa033025
  • Das, I., S. Mukhopadhyay, and H. Xu. 2013. “Individualized Dosing for Multiple Ordered Groups of Patients.” Journal of Statistical Theory and Practice 7 (1):95–106. doi:10.1080/15598608.2013.756348
  • Guo, B., and Y. Yuan. 2017. “Bayesian Phase I/II Biomarker-Based Dose Finding for Precision Medicine with Molecularly Targeted Agents.” Journal of the American Statistical Association 112 (518):508–20. doi:10.1080/01621459.2016.1228534
  • Mao, X., and Y. K. Cheung. 2017. “Sequential Designs for Individualized Dosing in Phase I Cancer Clinical Trials.” Contemporary Clinical Trials 63:51–8. doi:10.1016/j.cct.2016.08.018
  • McCullagh, P., and J. Nelder. 1989. Generalized Linear Models. Chapman and Hall/CRC Monographs on Statistics and Applied Probability Series. 2nd ed. London: Chapman & Hall/CRC.
  • Morita, S., P. F. Thall, and K. Takeda. 2017. “A Simulation Study of Methods for Selecting Subgroup-Specific Doses in Phase I Trials.” Pharmaceutical Statistics 16 (2):143–56. doi:10.1002/pst.1797
  • O’Quigley, J., M. D. Hughes, and T. Fenton. 2001. “Dose-Finding Designs for HIV Studies.” Biometrics 57 (4):1018–29. doi:10.1111/j.0006-341x.2001.01018.x
  • R Core Team. 2013. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
  • RStudio Team. 2021. RStudio: Integrated Development Environment for R. Boston, MA: RStudio, PBC.
  • Thall, P. F., H. Q. Nguyen, and E. H. Estey. 2008. “Patient-Specific Dose Finding Based on Bivariate Outcomes and Covariates.” Biometrics 64 (4):1126–36. doi:10.1111/j.1541-0420.2008.01009.x
  • Wathen, J. K., P. F. Thall, J. D. Cook, and E. H. Estey. 2008. “Accounting for Patient Heterogeneity in Phase II Clinical Trials.” Statistics in Medicine 27 (15):2802–15. doi:10.1002/sim.3109
  • Wijesinha, M. C., and S. Piantadosi. 1995. “Dose-Response Models with Covariates.” Biometrics 51 (3):977–87. doi:10.2307/2532998
  • Zhang, W., D. J. Sargent, and S. Mandrekar. 2006. “An Adaptive Dose-Finding Design Incorporating Both Toxicity and Efficacy.” Statistics in Medicine 25 (14):2365–83. doi:10.1002/sim.2325

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.